【摘要】 目的观察吉西他滨联合顺铂、地塞米松方案治疗复发性T细胞非霍奇金淋巴瘤(NHL)的疗效和毒副反应。方法全组18例,男性11例,女性7例。吉西他滨1000mg/m2,d1、8;顺铂25mg/m2,d1～3;地塞米松40mg/d,d1～4,21d为1周期。化疗≥2个周期,评定疗效,并随访疾病进展情况。结果12例有效,其中CR3例,PR9例,总有效率为66.67%,随访17例中位疾病进展时间4.1个月(1.5～29个月),1年生存率43.1%。毒副反应有中度的骨髓抑制、胃肠道反应和肝功损害。结论吉西他滨联合顺铂、地塞米松方案为复发性T细胞淋巴瘤的挽救方案,值得进一步应用。更多还原

【Abstract】 ObjectiveTo evaluate the effect and toxicity of gemcitabine combined with cisplatin and dexamethasone in the treatment of patients with relapsed T-cell non-Hodgkin’s lymphoma.MethodsOf the 18 patients with relapsed T-cell non-Hodgkin’s lymphoma,11 were male,7 were female. The chemotherapy regimen consisted of gemcitabine (1 000 mg/m2,d1,8),cisplatin (25 mg/m2,d1~3) and dexamethasone (40 mg/d,d1~4) given every three weeks. The clinical effects were evaluated after two circles by chemotherapy. The technique made a follow-up visit for the median time to progression of disease.ResultsOf the 18 patients,12 patients (66.67%) showed response including 3 patients who had complete response and 9 patients had partial response. After the follow-up,the median time to progression of disease was 4.1 months(1.5-29 months) and the survival probability at 1 year was 43.1%. Drug related toxic effects were medium bone marrow depression,gastrointestinal reactions and liver dysfunction.ConclusionThe combination of gemcitabine,cisplatin and dexamethasone is effective for patients with relapsed T-cell lymphoma. This regimen is worth applying to relapsed T-cell non-Hodgkin’s lymphoma.更多还原